- Home
- ANTE vs RNAZ Comparison
ANTE vs RNAZ Comparison
Compare ANTE & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTE
- RNAZ
- Stock Information
- Founded
- ANTE 2005
- RNAZ 2016
- Country
- ANTE China
- RNAZ United States
- Employees
- ANTE N/A
- RNAZ N/A
- Industry
- ANTE Advertising
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- ANTE Consumer Discretionary
- RNAZ Health Care
- Exchange
- ANTE Nasdaq
- RNAZ Nasdaq
- Market Cap
- ANTE 5.7M
- RNAZ 4.9M
- IPO Year
- ANTE N/A
- RNAZ 2021
- Fundamental
- Price
- ANTE $0.38
- RNAZ $3.55
- Analyst Decision
- ANTE
- RNAZ Strong Buy
- Analyst Count
- ANTE 0
- RNAZ 1
- Target Price
- ANTE N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- ANTE 105.0K
- RNAZ 82.6K
- Earning Date
- ANTE 01-03-2025
- RNAZ 11-14-2024
- Dividend Yield
- ANTE N/A
- RNAZ N/A
- EPS Growth
- ANTE N/A
- RNAZ N/A
- EPS
- ANTE 2.64
- RNAZ N/A
- Revenue
- ANTE $500,000.00
- RNAZ N/A
- Revenue This Year
- ANTE N/A
- RNAZ N/A
- Revenue Next Year
- ANTE N/A
- RNAZ $233.33
- P/E Ratio
- ANTE $0.14
- RNAZ N/A
- Revenue Growth
- ANTE N/A
- RNAZ N/A
- 52 Week Low
- ANTE $0.26
- RNAZ $3.21
- 52 Week High
- ANTE $2.90
- RNAZ $264.00
- Technical
- Relative Strength Index (RSI)
- ANTE 45.86
- RNAZ 23.28
- Support Level
- ANTE $0.39
- RNAZ $3.21
- Resistance Level
- ANTE $0.46
- RNAZ $8.46
- Average True Range (ATR)
- ANTE 0.06
- RNAZ 0.74
- MACD
- ANTE -0.00
- RNAZ -0.27
- Stochastic Oscillator
- ANTE 33.33
- RNAZ 6.44
About ANTE AirNet Technology Inc.
AirNet Technology Inc provides in-flight solutions to connectivity, entertainment, and digital multimedia in China. It offers Internet connections through a network of satellites and land-based beacons, provides airline travelers with interactive entertainment, and breaking news, and furnishes corporate clients with advertisements tailored to the perceptions of the travelers. The revenues are mainly derived from selling advertising time slots on the companies advertising networks and cryptocurrency mining.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.